Home Registration – Unanswered Questions

Best Exciting eMeet Biggest Conference 2019

King Street, United States

29 Sept, 2019

Become Volunteer

Professional Meetup '19

Why Best Professional eMeet 2019 ?

Morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, tristique senectus et netus et malesuada fames ac turpis egestas ultricies eget, tempor sit amet, ante. Donec eu libero sit amet quam egestas semper. Aenean ultricies mi vitae est. Mauris Eonec eu ribero sit amet quam egestas semper. Aenean are ultricies mi senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae vitae fames ac turpis egestas tristique senectus et netus.

Explore More About

500Usefull Sessions

50Great Speakers

7000Regular Crowd

50Skilled Speakers

Who’s Speaking

Welcome to the dedicated to building remarkable Speakers!

Schedule Plan

Welcome to the dedicated to building remarkable Schedule!

Best Exciting eMeet Biggest Conference 2019

King Street, United States

29 Sept, 2019

Professional Meetup '19

Why Best Professional eMeet 2019 ?

Who’s Speaking

Welcome to the dedicated to building remarkable Speakers!

Schedule Plan

Welcome to the dedicated to building remarkable Schedule!

Day 1:Friday

Day 2:Saturday

Session I: Neuroendocrine Tumours

Moderators: Faisal Albadainah

9:00-9:20

Overview of NET

9:20-9:40

Liver directed therapy in metastatic NET: benefits and risks

9:40-10:00

Speaker: Role of nuclear medicine in NET: diagnosis and treatment

10:00-10:20

Discussion

Session II: GI cancers

Panel: Ali Aljubran, Emad Tashkandi, Mohamed Alqarni, Kanaan Alshemari, Mervat Mahrous, Khalid Alsaleh, Abderlrahim Shanqeeti

10:20-11:00

MSI-H CRC -Do we need TMB assessment as well? -Immunetherapy with extensive visceral metastasis -What to give after failure of 1st line immunotherapy? -Locally advancer MSI-H CRC: what to give as an adjuvant therapy?

Moderator: Mohamed Alqani

11:00-11:40

Pancreatico-biliary cancers -Neoadjuvant therapy in resectable pancreatic cancer Duration of neoadjuvant chemotherapy Role of chemoradiotherapy Molecular tests in pancreaticobiliary cancer

Moderator: Khalid Alsaleh

Session III: GI cancers

Panel: Shouki Bazarbashi, Mohamed Alghamdi, Hani Elkhatib, Abdullah Alsharm, Fahed Ibn Shamsa, Waleed Selwi, Samah Alraheli

14:00-14:40

Rectal cancer -Organ preservation in T1/T2 rectal cancer -Watch and wait in rectal cancer -Induction vs consolidation chemotherapy -Adjuvant chemotherapy:Yes or no

Moderator: Mohamed Alghamdi

14:40-15:20

GI cancer with Peritoneal carcinomatosis -HIPEC in advanced CRC -Chemotherapy component with HIPEC -Role of perioperative chemotherapy with CRS/HIPEC -HIPEC in gastric cancer

Moderator: Abdullah Alsharm

15:20-16:00

1st line metastatic CRC -Anti-EGFR with triplet -HER2 test before 1st line antiEGFR/Anti-EGFR with BRAF mutation -Doublet vs triplet in V600E BRAF mutation

Moderator: Waleed Selwi

Session IV: Hepatobiliary Tumours

Moderators: Marwan Al-Hejaili - Abdelaziz Tashkandi

16:00-16:20

Cholangiocarcinoma treatment approaches of intrahepatic vs extrahepatic??

16:20-16:40

Periampullary carcinoma: optimal therapeutic management

16:40-17:00

Role of antiviral therapy in patients with HCC

17:00-17:20

Discussion

Session I: Early Breast Cancer

Panel: Panel: Meteeb Alfohaidi, om Alkhair Aboelkhair, Adher Alsayed, Abdullah Alzahrani, Ahmed Alshehri, Jamal Zekri, Ahmed Alwabari, Ahmed Zeeneldin

9:00-9:40

Adjuvant therapy in HER2-positive breast cancer trastuzumab 6 vs 12 months role of pertuzumab/niratinib

Moderator: Om Alkhair Aboelkhair

9:40 –10:20

Adjuvant hormonal therapy what is the optimal duration, duration of LHRH-analougues Lobular breast cancer N1 disease/molecular tools

Moderator: Abdullah Alzahrani

10:20-11:00

Triple negative breast cancer (Non-metastatic): Neoadjuvant immunetherapy/ platinum Postneoadjuvant therapy, PARPi in BRCA mutant

Moderator: Ahmed Alwabari

11:00-11:20

Break

Session II: Advanced breast cancer

Panel: Aboelkhair Algahami, Ahmed Alrefaei, Shereef Elsamany, Abdullah Altwergi, Shadi Khayat, Essam Murshid, Atlal Abusanad, Nedal Bukhari

11:20-12:00

HR-positive/HER2-negative breast cancer OS with CDK4-6 inhibitors: impact on treatment selection Alpelisib vs. everolimus in 2nd line Early progression after CDK4-6i: chemotherapy vs hormonal therapy Visceral crisis: duration of chemotherapy, role of maintenance hormonal therapy?

Moderator: Ahmed Alrefaei

12:00-12:40

Advanced HER2-positive breast cancer Position of ADC Can we use ADC after another ADC treatment sequence Hormonal therapy+antiHER2 in 1st line

Moderator: Abdullah Altwergi

12:40-13:20

Triple negative breast cancer Platinum vs PARPi/ can we use one after the other? can we use PARPi beyond BRCA1/2 mutations PARPi in1st line or later lines Immune therapy: Pembro vs atezolizumab in 1st line Can we use immunetherapy in 2nd line after chemotherapy /PARPi

Moderator: Essam Murshid

13:20-14:30

Prayer &Lunch

Session IV Hematological malignancies

Session 1 (Plasma Cell Disorders)

Khalofa Alghamdi - Ashraf Warsi

14:30-15:00

Panel:
Ali Aljubran, Emad Tashkandi, Mohamed Alqarni, Kanaan Alshemari, Mervat Mahrous, Khalid Alsaleh, Abderlrahim Shanqeeti

MSI-H CRC
-Do we need TMB assessment as well?
-Immunetherapy with extensive visceral metastasis
-What to give after failure of 1st line immunotherapy?
-Locally advancer MSI-H CRC: what to give as an adjuvant therapy?

Pancreatico-biliary cancers
-Neoadjuvant therapy in resectable pancreatic cancer
Duration of neoadjuvant chemotherapy
Role of chemoradiotherapy
Molecular tests in pancreaticobiliary cancer

Panel:
Shouki Bazarbashi, Mohamed Alghamdi, Hani Elkhatib, Abdullah Alsharm, Fahed Ibn Shamsa, Waleed Selwi, Samah Alraheli

Rectal cancer
-Organ preservation in T1/T2 rectal cancer
-Watch and wait in rectal cancer
-Induction vs consolidation chemotherapy
-Adjuvant chemotherapy:Yes or no

GI cancer with Peritoneal carcinomatosis
-HIPEC in advanced CRC
-Chemotherapy component with HIPEC
-Role of perioperative chemotherapy with CRS/HIPEC
-HIPEC in gastric cancer

1st line metastatic CRC
-Anti-EGFR with triplet
-HER2 test before 1st line antiEGFR/Anti-EGFR with BRAF mutation
-Doublet vs triplet in V600E BRAF mutation

Moderators:
Marwan Al-Hejaili - Abdelaziz Tashkandi

Panel:
Panel: Meteeb Alfohaidi, om Alkhair Aboelkhair, Adher Alsayed, Abdullah Alzahrani, Ahmed Alshehri, Jamal Zekri, Ahmed Alwabari, Ahmed Zeeneldin

Adjuvant therapy in HER2-positive breast cancer
trastuzumab 6 vs 12 months
role of pertuzumab/niratinib

Adjuvant hormonal therapy
what is the optimal duration, duration of LHRH-analougues
Lobular breast cancer
N1 disease/molecular tools

Triple negative breast cancer (Non-metastatic):
Neoadjuvant immunetherapy/ platinum
Postneoadjuvant therapy,
PARPi in BRCA mutant

Panel:
Aboelkhair Algahami, Ahmed Alrefaei, Shereef Elsamany, Abdullah Altwergi, Shadi Khayat, Essam Murshid, Atlal Abusanad, Nedal Bukhari

HR-positive/HER2-negative breast cancer
OS with CDK4-6 inhibitors: impact on treatment selection
Alpelisib vs. everolimus in 2nd line
Early progression after CDK4-6i: chemotherapy vs hormonal therapy
Visceral crisis: duration of chemotherapy, role of maintenance hormonal therapy?

Advanced HER2-positive breast cancer
Position of ADC
Can we use ADC after another ADC
treatment sequence
Hormonal therapy+antiHER2 in 1st line

Triple negative breast cancer
Platinum vs PARPi/ can we use one after the other?
can we use PARPi beyond BRCA1/2 mutations
PARPi in1st line or later lines
Immune therapy: Pembro vs atezolizumab in 1st line
Can we use immunetherapy in 2nd line after chemotherapy /PARPi